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(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.) 1st Editorial Decision 14 September 2010
Thank you for submitting your manuscript for consideration by the EMBO Journal. It has now been seen by three referees whose comments are enclosed. As you will see, all three referees express interest in your work, but while referee 1 has no major criticisms, referees 3 and particularly 2 do raise a number of concerns that would need to be addressed before we could consider publication of your study. In particular, I would draw your attention to referee 2 point 1 regarding the need for further biochemical data to definitively determine the mechanism of autoimmune escape. In addition, referee 3 (point 2) argues that, in the absence of mutagenesis data, it is not possible to draw firm conclusions as to which CDR loops in the TCR are important for the docking interaction. Since this is an important part of your manuscript, and given that the referees (especially #2) find this to be an interesting aspect of your structural analysis, I would strongly encourage you to undertake the necessary mutagenesis to strengthen your conclusions on this point. Finally, both referees 2 and 3 highlight a number of discussion points that need to be expanded and/or amended to better emphasise how your work relates to previous studies, as well as putting it into the context of the underlying biology.
In the light of the referees' positive recommendations, I would therefore like to invite you to submit a revised version of the manuscript, addressing all the comments of all three reviewers. I should add that it is EMBO Journal policy to allow only a single round of revision. Acceptance of your manuscript will thus depend on the completeness of your responses included in the next, final version of the manuscript. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process initiative, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as a standard revision time, and as a matter of policy, we do not consider any competing manuscripts published during this period as negatively impacting on the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely,
Editor
The EMBO Journal
REFEREE REPORTS
Referee #1 (Remarks to the Author):
This is an interesting paper that, in a nutshell, describes how a human autoimmune TCR may escape negative selection in the thymus yet become activated in the periphery through a compensation mechanism whereby weak peptide binding is countered by maximizing TCR contacts with the MHCp surface in order to achieve the high affinity seen for anti-microbial TCR complexes.
The structural work is very solid and it is an interesting model to explain autoreactive TCRs. Certainly, given that the IAu-MBP TCRs all bind in a 'canonical' mode like MS2-3C8, and they also have relatively high affinities despite weakly binding peptides, this could be a general mechanism for the paradox of thymic escape and yet peripheral activation. The hypothesis the authors put forth is certainly testable, and if I had one minor criticism it would be that it would be nice to see at least some effort in that direction here. Nevertheless, I find it acceptable for publication in EMBO given that we have not seen a 'canonical' human autoimmune TCR binding footprint so far and it is important to dispel the notion that all human autoreactive TCRs bind in some odd fashion.
Referee #2 (Remarks to the Author):
The article by Yin et al. entitled « Structural basis for escaping negative selection revealed by TCR with high affinity for self antigen » describes the structure of an autoimune TCR, MS2-3C8, in complex with a fragment of myelin basic protein, MBP-111-129, presented by a class II MHC molecule, HLA-DR4. This is the sixth TCR-peptide-MHC class II complex structure illustrating the recognition of a self-antigen involved in an autoimmune disease by a TCR. The authors have also characterized the TCR-peptide-MHC binding by the SPR technique, providing the kinetic parameters of this interaction. MBP-111-129 is an immuno-dominant epitope in HLA-DR4+ MS patients and the MS2-3C8 TCR has been identified as beeing involved in the disease relapse in one individual. Therefore, the data presented in this article should help in understanding some fundamental mechanisms that led to autoimmune diseases. The authors claim that their data shed light on one of the mechanism by which autoreactive T cells may escape the negative selection in the thymus. This mechanism is based on the low affinity of the self-peptide for the MHC that is in part compensated by the high affinity of the TCR for the peptide-MHC complex. The work is technically sound and this new TCR-peptide-MHC structure truly complements the quite sparse database of autoimmune TCR in complex with their cognate ligand. However, the result section provides a too much detailed description of the structure that is detrimental to the immunological messages. There is also some weakness in the discussion (see below for the details) and the biological relevance of the work should be emphasized in both the results and the discussion sections, given the quite wide readership of the EMBO Journal. In the present state, I feel this article would be better suited for publication in a more specialized journal. If the authors could resolve the ambiguity about the mechanism pointed in (1) and more explicitly present the immunological relevance of their findings, then the paper might be suitable for publication in the EMBO Journal.
Please find below the list of more specific comments:
1 -The data presented in this paper may not be sufficient to unambiguously identify the mechanism by which the MS2-3C8 TCR has escaped the negative selection. The affinity measurements are made with a construct in which the peptide is covalently attached to N-ter end of the HLA beta chain through a peptidic linker (a construct widely used for producing peptide-MHC class II). The authors mention that the TCR affinity for the peptide-MHC could thus be overestimated, since the linker may artificially stabilize the peptide-MHC complex (see page 7). Knowing the precise impact of the linker on the kinetic parameters of the MS2-3C8 -MBP-111-129 -HLA-DR4 interaction would actually strengthen the discussion. If the low affinity of the peptide for the MHC molecule reduces the TCR-peptide-MHC half-life to values close to that observed for Ob.1A12 and 3A6, one can argue that these three TCR share a common mechanism of escape, based on a sub-optimal affinity for their cognate peptide-MHC. On the other hand, if the linker has no significant impact on the dissociation rate of the MS2-3C8 -MBP-111-129 -HLA-DR4 complex, we are truly in presence of an alternate mechanism, in which the lower life time of the peptide-MHC complex (i.e. the lower number of peptide-MHC present at the cell surface) could be compensated by a much higher affinity of the TCR, at least in the periphery. Is the yield of MHC refolding with the unlinked peptide so low that SPR measurements would be untractable (very few amount of MHC are needed for its immobilization on the SPR chip)? Is there any data on the half life of the MBP-111-129 -HLA-DR4 complex that could provides indications on the feasibility of such a measure and help to compare with other autoimmune epitopes (as MBP-Ac1-11 presented by I-Au)? The TCR-peptide-MHC dissociation measured is extremely slow. As this seems to be the thermodynamic parameter that correlates the most with the T cell activation, this unusual value may deserve a more detailed discussion. 2 -The structure of the MS2-3C8 TCR in complex with MP-111-129 -HLA-DR4 shows that the TCR adopts the canonical diagonal mode of docking, with the TCR focusing on the central region of the peptide, at odds with the two structures of human autoimmune TCR (Ob.1A12 and 3A6) previously determined. This observation should be more carefully discussed as it seems to invalidate the hypothesis of a specific mode of docking for autoimmune TCR proposed before (Hahn et al., 2005) . 3 -The present structure is not the first autoimmune TCR structure in complex with a peptide having a low affinity for its MHC molecule. As mentioned by authors, 172.10 TCR, in complex with MBPAc1-11 bound to I-Au is another example of such a TCR that recognizes an unstable peptide (the half life of these peptide-MHC complex is < 15mn). In this case, linking the wild type peptide to the beta chain was not sufficient to stabilize it: the structural bases for this instability were investigated and a higher affinity (~ 1000 fold) peptide mutant (K4Y) had to be produced. The affinity of the 172.10 for its cognate peptide MHC is similar to that of MS2-3C8 TCR: 5 uM. The paper really lacks a more in depth comparison with this TCR as it seems that both TCR share the same mechanism of negative selection escape. 4 -The fact that the peptide is essentially recognized by the CDR3beta, with a specific focus on Arg7 is remarkable. Investigating the structural basis underlying the restrained T cell repertoire that can interact with MBP-111-129 -HLA-DR4 may be worth it. Comparison of the peptide centered recognition mode of this TCR with the MHC centered recognition mode observed in 172.10 TCR may also be valuable. 5 -The section on the structural basis for weak binding of MBP to HLA-DR4 could be shortened, as it lacks other experimental data such as binding data on peptide variants to confirm the structural observations. 6 -The section on the possible role of post-translational modification (discussion, page 17) looks somehow disconnected from the discussion, as data supporting the possible modification of MBP-111-129 and/or the improved binding of such modified peptides are not provided. 7 -The section on the MS2-3C8 -HLA-DR4 could be shortened and focused on the essential characteristics. If the contribution of the CDR3beta is remarkable, the contribution of the germline encoded regions still accounts for about 50% of the TCR contribution (56% of the buried surface and about 50% of the contacts as depicted in table II) and the sentence of the discussion page 18 (" ..., the majority of the contacts to MHC helices are made by somatically generated CDR3 loops, ...") is thus misleading. In Ob.1A12 TCR, the contribution of the germline encoded regions is close to 30% (see table 3 of Rudolph et al. 2006) and is thus significantly lower than the one observed in MS2-3C8 TCR. 8 -Page 11, section "Interaction of TCR MS2-3C8 with HLA-DR4": As shown in tables 2 and 3 of Rudolph et al ., 2006 , the Vbeta domain of BM3.3 TCR also dominates (63%) the interaction with the cognate pBM1-H-2Kb. This TCR-peptide-MHC structure should therefore be cited in the text. Table I : A value of 40.2 for the overall multiplicity of the crystallographic data is unusually high and differs very much from the one in the last resolution shell: is this a typo ?
-
Referee #3 (Remarks to the Author):
The Mariuzza lab report an interesting finding that principally concerns the structure of an autoimmune-pMHC-II complex. This work stems from a series of studies on autoimmune TCR complexes, where the initial posit was that auto-immune TCR complexes adopt unusual docking topologies wrt "microbial" TCR-pMHC complexes.
Clearly to test such generalities, more TCR-pMHC complexes are required, and this study nicely shows that auto-reactive TCR complexes can adopt standard TCR-pMHC docking topologies -what a standard docking topology however is a matter of some debate. The structures are expertly determined, analysed well and the associated SPR data is well done. In my view, the manuscript is suitable for publication in EMBO, as long as they can address some concerns.
1) It is incorrect to globally state that microbial TCRs dock centrally on pMHC. There are a number of reports that demonstrate N-terminal or C-terminal docking topologies for such complexes. For example, the avoidance of self-tolerance story (Gras et al., Immunity 2009) demonstrates an Nterminal docking footprint. Further this complex interacts with reasonably high affinity, so it is also incorrect for the authors to state that N-terminal docking topologies = low affinity.
2) Unless the authors wish to conduct extensive site-directed mutagenesis at the interface, the authors cannot state what CDR loops etc control the docking orientation. Indeed, the authors appear to be confused about this point, as at one stage they describe the CDR1/2 loops engendering a conserved docking footprint, and later on in the paper they ascribe this function to a CDR3 loop.
3) To strengthen the novelty of their work, the authors have polarised their arguments with regard to sweeping generalisations pertaining to the differing role the CDR loops have in interacting with the peptide. Further, most of the field consider that CDR1/2 dominate interaction with MHC, CDR3 loops interact with peptide -so their analysis that this is not the case is surprising. The authors need to clarify and expand on this section, embracing recent work and citing examples where the generalities don't hold true.
other:
BSA values are too accurate The SPR data does not show error bars (Fig. 1b , equilibrium binding curve) and uncertain how many times this experiment was done.
1st Revision -authors' response 13 December 2010
Reply to Referee #1
We thank the reviewer for his/her appreciation of our study. We certainly agree that our hypothesis that high-affinity TCRs can successfully target self-peptides with unfavorable MHCbinding properties to cause autoimmunity is testable. However, this would require in vivo experiments involving transgenic mice which we believe are beyond the scope of the present study. Nevertheless, the revised manuscript contains new data that could serve as the basis for designing such experiments. In particular, we have identified a mutant of TCR MS2-3C8 (CDR1α Thr29Ala) that binds MBP-HLA-DR4 with 12-fold higher affinity than the wild-type TCR (K D = 0.42 µM versus 5.0 µM for wild-type) (Table III) . Previously, mice transgenic for MS2-3C8 and HLA-DR4 were shown to develop EAE, demonstrating that MS2-3C8 T cells escaped thymic selection yet underwent peripheral activation [Quandt et al. J. Exp. Med. 200, 223-243 (2004) ]. What would be the phenotype of mice transgenic for the MS2-3C8 CDR1α Thr29Ala mutant and HLA-DR4? Would the 12-fold enhanced affinity of the mutant prevent T cells expressing this TCR from escaping negative selection? If not, would these mice develop more severe EAE, or EAE with different clinical features? These are among the biological questions that can now be addressed using our structural and binding data on the MS2-3C8-MBP-DR4 autoimmune complex.
Reply to Referee #2
We thank the referee for the thorough review of our manuscript, and for bringing to our attention important issues to address: Response: The peptide linker we used to stabilize the MBP 114-126-HLA-DR4 ligand should have no effect on the binding of TCR MS2-3C8. In the crystal structure, the linker makes no contacts with the TCR. Although the linker is visible in one of the two complexes in the asymmetric unit, this is due to crystal contacts with the Cβ domain of a neighboring complex molecule. No electron density was visible for the linker peptide in the other complex, indicating flexibility (p. 9, 1 st paragraph). As pointed out by the reviewer, peptide linkers are widely used to stabilize peptide-MHC class II complexes for TCR affinity measurements, including the MBP Ac1-11-I-A u ligand recognized by TCR 172.10.
We agree with the reviewer that, ideally, we should measure TCR affinity for MBP-DR4 in the absence of linker. However, this was not possible due to the extremely weak interaction between MBP 114-126 and HLA-DR4, which prevented production of stable ligand for SPR measurements, despite numerous attempts. That is, HLA-DR4 refolded with unlinked MBP dissociated into α and β chains during purification. Loading MBP into HLA-DR4 produced using Drosophila cells was also unsuccessful. Indeed, the low affinity of MBP 114-126 for HLA-DR4 is well documented in the literature. In one study, MBP 114-126 was found to bind HLA-DR4 ~75-fold less tightly than HA 307-319 [Muraro et al. J. Clin. Invest. 100, 339-349 (1997) ]. In an independent study, the affinity of MBP 114-126 for HLA-DR4 was estimated at ~2000 nM, which is decidedly in the low range for peptide-MHC interactions [Valli et al. J. Clin. Invest. 91, 616-628 (1993) ]. We cite both studies in the revised manuscript (p. 7, 1 st paragraph). We do not believe we have overestimated the intrinsic affinity of MS2-3C8 for its MBP-DR4 ligand. The overall stability of the TCR-peptide-MHC ternary complex is determined by two interactions: 1) binding of peptide to MHC and 2) binding of TCR to peptide-MHC. By covalently attaching MBP to DR4, we have, in effect, eliminated interaction #1 from the equation, allowing us to measure the intrinsic affinity of MS2-3C8 for MBP-DR4. This approach is analogous to the one used by Garcia et al. to characterize the interaction of TCR 172.10 with MBP-I-A u , in which the MBP peptide was mutated to increase its affinity for I-A u to permit SPR measurements [Proc. Natl. Acad. Sci. USA 98, 6818-6823 (2001) ].
Of course, in the biological situation, the weak binding of MBP to HLA-DR4 (like the weak binding of MBP to I-A u ) would destabilize the overall TCR-peptide-MHC ternary complex. This situation is very different from the interaction of TCRs Ob.1A12 and 3A6 with their MBP-HLA-DR2 ligands, in which the MBP peptide binds very tightly to MHC (interaction #1), but the TCRs bind very weakly to peptide-MHC (interaction #2). By contrast, for autoimmune TCRs MS2-3C8 and 172.10, interaction #1 is weak but interaction #2 is strong, demonstrating an alternative mechanism for destabilizing for the TCR-peptide-MHC recognition unit and escaping negative selection.
"The TCR-peptide-MHC dissociation measured is extremely slow. As this seems to be the thermodynamic parameter that correlates the most with the T cell activation, this unusual value may deserve a more detailed discussion."
Response: We thank the reviewer for calling our attention to the unusually slow off-rate of TCR MS2-3C8. We have now addressed this point in the Discussion (p. 18, 2 nd paragraph):
The exceptionally slow off-rate of MS2-3C8 is notable, since off-rate appears to be the binding parameter that correlates best with T cell responsiveness (van der Merwe and Davis, 2003; Stone et al, 2009 ). We propose that the tight binding of MS2-3C8 to MBP-DR4, and especially the slow offrate of this interaction, overcome the weak binding of MBP to HLA-DR4 to sufficiently stabilize the TCR-peptide-MHC ternary complex to permit T cell activation at high myelin antigen concentrations, particularly once a naïve MS2-3C8-bearing T cell has differentiated into a memory cell with reduced co-receptor requirements for activation or at high myelin antigen concentrations, such as may be encountered in the CNS.
'The structure of the MS2-3C8 TCR in complex with MBP 111-129-HLA-DR4 shows that the TCR adopts the canonical diagonal mode of docking, with the TCR focusing on the central region of the peptide, at odds with the two structures of human autoimmune TCR (Ob.1A12 and 3A6) previously determined. This observation should be carefully discussed as it seems to invalidate the hypothesis of a specific mode of docking for autoimmune TCR proposed before (Hahn et al., 2005)"
Response: We agree that MS2-3C8 differs from Ob1A12 and 3A6 in that MS2-3C8 docks in the canonical diagonal orientation. We also agree that this contradicts the original hypothesis of Hahn et al. (2005) that autoimmune TCRs must adopt unusual docking topologies. However, it is important to note this hypothesis was recently updated to account for new data: Wucherpfennig, Call, Deng and Mariuzza. Structual alterations in peptide-MHC recognition by self-reactive T cell receptors. Curr. Opin. Immunol. 21, 590-595 (2009) . In essence, two broad categories of autoimmune TCRs may now be distinguished: 1) TCRs with altered binding topologies to self-peptide-MHC (Ob.1A12, 3A6) and 2) TCRs that bind self-peptide-MHC in the canonical orientation, but where there are structural defects or suboptimal anchors in the self-ligand (172.10, MS2-3C8). The critical point is that, in both cases, the overall stability of the TCR-peptide-MHC recognition unit is markedly reduced, allowing the autoreactive T cells to escape negative selection. As requested, we have clarified this issue in the revised Discussion (p. 18, 1 st paragraph):
Based on the available structures of autoimmune TCR-peptide-MHC complexes, two broad categories of self-reactive TCRs may now be distinguished: 1) TCRs with altered binding topologies to self-peptide-MHC (Ob.1A12, 3A6) and 2) TCRs that bind self-peptide-MHC in the canonical diagonal orientation, but where there are structural defects or suboptimal anchors in the self-ligand (172.10, MS2-3C8). For both categories, however, the overall stability of the TCRpeptide-MHC recognition unit is markedly reduced, allowing the autoreactive T cells to escape negative selection (Wucherpfennig et al, 2009 Response: We completely agree with the reviewer that MS2-3C8 shares important features with 172.10, and that these TCRs may have escaped negative selection through similar mechanisms. We have provided more details on these similarities (and differences) in the revised manuscript: (p. 7, 2 nd paragraph)
It also binds far more tightly than do human autoimmune TCRs 3A6 and Ob.1A12 (K D > 100 µΜ) (Li et al, 2005; Appel et al, 2000) , but similarly to mouse autoimmune TCR 172.10 (6 µM) (Garcia et al, 2001) . Moreover, the off-rate of the interaction (0.011 s -1 , corresponding to a half-life of 69 s) is exceptionally slow, compared to the off-rates of all other TCR-peptide-MHC interactions characterized to date (0.02 to >1 s -1 ) (Cole et al, 2007) . For TCR 172.10, the off-rate of its interaction with MBP-I-A u is ~20-fold faster (0.22 s -1 ) (Garcia et al, 2001 ). The slow off-rate of MS2-3C8 is counterbalanced by a very slow on-rate (1.7 × 10 3 M -1 s -1 ) relative to the on-rates of other TCRs (2 × 10 3 to >1 × 10 6 M -1 s -1 ), including 172.10 (3.7 × 10 4 M -1 s -1 ), which may imply conformational changes in MS2-3C8 and/or MBP-DR4 during complex formation.
(p. 9, 2 nd paragraph) Thus, MS2-3C8 docks symmetrically over MBP-DR4 in a canonical diagonal orientation, with a crossing angle of TCR to peptide-MHC (Reinherz et al, 1999) of 65 o , compared with 70 o for the HA1.7-HA-DR4 complex. Importantly, mouse autoimmune TCR 172.10 also recognizes its selfligand in a canonical manner (Maynard et al, 2005) , implying that MS2-3C8 and 172.10 use similar mechanisms to escape negative selection (see Discussion).
(pp. 20-21)
The human MS2-3C8-MBP-DR4 complex shares certain features with the complexes between three mouse TCRs (172.10, 1934 .4 and cl19) and MBP-I-A u (Maynard et al, 2005; Feng et al, 2007) , but also presents significant differences. Like MS2-3C8, TCRs specific for MBP-I-A u recognize their self-ligand via a canonical docking orientation (Maynard et al, 2005; Feng et al, 2007) . However, the MBP-I-A u ligand is unusual in that the N-terminal one-third of the binding groove is empty (He et al, 2002) . The groove contains only the first seven residues of the MBP Ac1-11 peptide, leaving the P1 and P2 pockets of I-A u unoccupied, which likely explains the short half-life of the structurally defective MBP-I-A u complex. By contrast, the binding groove of HLA-DR4 is completely filled by MBP 114-129, although portions of the peptide are loosely accommodated. As a consequence of partial occupancy of the I-A u binding groove by MBP Ac1-11, TCRs 172.10, 1934.4 and cl19 only recognize six peptide residues (P3 to P8), compared with nine (P-1 to P8) in the case of MS2-3C8.
While both MS2-3C8 and 172.10 engage their respective ligands in a canonical diagonal orientation, the relative contributions of the CDR loops to MHC recognition differ markedly in the two complexes: whereas the CDR3α and CDR3β loops of MS2-3C8 together account for 52% of total contacts to MHC, the corresponding contribution of the CDR3 loops of 172.10 is only 32%. Indeed, MS2-3C8 is remarkable insofar as the somatically generated CDR3 loops contribute as much to MHC recognition as the germline-encoded CDR1 and CDR2 loops. In most other TCRpeptide-MHC class II complexes, by contrast, with the notable exception of the autoimmune Ob1A12-MBP-DR2b complex (Hahn et al, 2005) , CDR1 and CDR2 mediate the prevalence of contacts to MHC (Rudolph et al, 2006) . In addition, whereas the interaction of TCRs 172.10, 1934.4 and cl19 with MBP Ac1-11 is characterized by a paucity of specific contacts between TCR and peptide (Maynard et al, 2005; Feng et al, 2007) , such structural degeneracy is not evident in the interface of MS2-3C8 with MBP 114-129, which possesses high shape and chemical complementarity. In conclusion, the MS2-3C8-MBP-DR4 structure provides a framework for understanding how autoreactive T cells can successfully target pathogenic self-epitopes with unfavorable MHC-binding properties that may nevertheless be dominant in human autoimmune disease. Response: We concur with the reviewer that the dominant role of CDR3β in peptide recognition is remarkable. We also agree that it would be interesting to investigate the structural basis for the restricted TCR repertoire elicited by MBP 111-129 in HLA-DR4-positive MS patients. However, this would require immunological studies of human subjects (MS patients and healthy individuals) which we believe are beyond the scope of the present work. With respect to TCR 172.10, we have included a more detailed comparison with MS2-3C8 in the revision, as requested (Point #3).
"The fact that the peptide is essentially recognized by the

"The section on the structural basis for weak peptide binding to HLA-DR4 could be shortened…"
Response: As requested, we have shortened this section to highlight the key features of the MBP-HLA-DR4 interaction (pp. 10-11). Response: The reviewer is correct that there are no actual data supporting the hypothesis that posttranslational modifications of MBP 111-129 might improve binding to HLA-DR4. Accordingly, we have removed this section from the Discussion.
"The section on the MS2-3C8-HLA-DR4 interaction could be shortened and focused on the essential characteristics."
Response: We have shortened this section as requested (pp. 11-13) .
"If the contribution of the CDR3β is remarkable, the contribution of the germline encoded regions still accounts for about 50% of the TCR contribution (56% of the buried surface and about 50% of the contacts as depicted in Table II ) and the sentence of the discussion page 18 ("…the majority of the contacts to MHC helices are made by somatically generated CDR3 loops…") is thus misleading. In Ob.1A12 TCR, the contribution of the germline encoded region is close to 30% … and is thus significantly lower than the one observed in MS2-3C8 TCR."
Response: As shown in Table II , the somatically generated CDR3α and CDR3β loops of MS2-3C8 together account for 52% of total van der Waals contacts to HLA-DR4 (40 of 76 contacts), with CDR3β making by far the greater contribution (35 contacts). The reviewer is therefore correct that the germline-encoded CDR1 and CDR2 loops of MS2-3C8 still account for ~50% of total contacts to MHC. What is notable about MS2-3C8 is the relatively large contribution made by its CDR3 loops (particularly CDR3b) to contacting MHC, compared to other MHC class II-restricted TCRs, as seen in the In the revision, we also addressed the functional contribution of selected CDR residues to binding MBP-DR4 by site-directed mutagenesis. These new data, and their interpretation, are presented in the revised Results (p. 15-17):
Mutational analysis of TCR MS2-3C8 binding to MBP-HLA-DR4
To assess the functional contribution of germline-encoded CDR1/CDR2 versus somatically generated CDR3 loops to complex formation, six CDR residues were selected for alanine mutagenesis: CDR1α Thr29, CDR3α Lys96, CDR2β Glu50, CDR2β Thr55, CDR3β Ser98, and CDR3β Asn100. In the MS2-3C8-MBP-DR4 structure, CDR1α Thr29 makes multiple contacts with HLA-DR4 Thr77β and His81β ( Figure 5C ), CDR2β Glu50 forms a salt bridge with HLA-DR4 Lys67α ( Figure 5D ), and CDR2β Thr55 makes a side-chain-side-chain hydrogen bond with HLA-DR4 Lys39α ( Figure 5D ). In addition, all three germline-encoded residues occur at positions believed to control the conserved diagonal orientation of TCR on MHC (Marrack et al, 2008) . Surprisingly, mutation of CDR2β Glu50 or CDR2β Thr55 to alanine had minimal effect on binding (K D = 6.0 µM and 6.8 µM, respectively, compared to 5.0 µM for wild-type MS2-3C8) (Figure 1E, F ;  Table III ), while mutation of CDR1α Thr29 to alanine actually increased affinity 12-fold (0.42 µM) ( Figure 1C ). Mutation of CDR3α Lys96 also had little effect on binding (K D = 6.0 µM) ( Figure 1D ), despite the involvement of this residue in a side-chain-side-chain hydrogen bond with HLA-DR4 Gln57α ( Figure 6A ). In sharp contrast, alanine substitution of CDR3β Ser98 or CDR3β Asn100 abolished binding nearly completely ( Figure 1G, H) . In the MS2-3C8-MBP-DR4 structure, CDR3β Ser98 makes 14 van der Waals contacts and one side-chain-side-chain hydrogen bond with HLA-DR4 ( Figure 6B ; Table II) , as well as one main-chain-main-chain hydrogen bond with the MBP peptide (Figure 7 ). Since truncation of CDR3β Ser98 to alanine should still permit formation of the main-chain-main-chain hydrogen bond, this mutation should mostly affect interactions with HLA-DR4. Similarly, CDR3β Asn100 makes six contacts and one hydrogen bond with HLA-DR4 ( Figure 6B ; Table II ), compared to only one contact with MBP.
These mutagenesis experiments, though not exhaustive, support our conclusion from the crystal structure that CDR3β, which accounts for more of the binding interface with HLA-DR4 than any other CDR (see above), has a major role in MHC recognition. In this respect, MS2-3C8 differs from the mouse MHC class I-restricted TCR 2C, whose most important energetic interactions are contributed by CDR1 and CDR2 (Manning et al, 1998; Lee et al, 2000) . It is, however, remarkably reminiscent of the human MHC class I-restricted TCR LC13, whose CDR3 loops dominate peptide-MHC recognition, with CDR1 and CDR2 having only minor energetic roles (Borg et al, 2005) . Tables 2 and 3 of Rudolph et al. 2006 Indeed, only three other complexes displaying a similar degree of Vβ dominance as MS2-3C8-MBP-DR4 have been reported, involving the HLA-A2-restricted TCR JM22 (67%) (Stewart-Jones et al, 2003) , the H-2K b -restricted TCR BM3.3 (63%) (Reiser et al, 2003) , and the MBP-specific TCR 3A6 (61%) (Li et al, 2005) .
"As shown in
"Table I: A value of 40.2 for the overall multiplicity of the crystallographic data is unusually high and differs very much from the one in the last resolution shell: is this a typo?"
Response: We have corrected this error in Table I .
Reply to Referee #3
We are grateful to the reviewer for his/her appreciation of our study, and for bringing to our attention important points to address:
1. "It is incorrect to globally state that microbial TCRs dock centrally on pMHC. There are a number of reports that demonstrate N-terminal or C-terminal docking topologies for such complexes. For example, the avoidance of self tolerance story (Gras et al., 2009) demonstrates an N-terminal docking footprint. Further this complex interacts with reasonably high affinity, so it is also incorrect for the authors to state that N-terminal docking topologies = low affinity."
Response: We agree with the reviewer that there are important exceptions to the central docking orientation observed for most anti-foreign TCRs. We have revised the Introduction accordingly in order to avoid unwarranted generalizations (p. 4, 1 st paragraph):
Although anti-microbial TCRs usually adopt a central diagonal orientation, deviations from this topology have been described (Ely et al, 2008) . For example, an MHC class I-restricted TCR (CF34)
